2007 Releases

Lenalidomide Effective in CLL Carrying Chromosomal Abnormalities: Dec-11-2007 — Asher A. Chanan-Khan, MD, RPCI, reports on studies demonstrating the clinical efficacy of lenalidomide in treating patients with chronic lymphocytic leukemia characterized by chromosomal abnormalities at the 49th Annual Meeting of the American Society of Hematology.
New Tool for Diagnosing and Assessing Gastrointestinal Graft vs. Host Disease: Dec-10-2007 — Wireless capsule endoscopy is a useful tool in the management of gastrointestinal graft vs. host disease following allogeneic hematopoietic stem cell transplant, according to study presented by researchers from RPCI at the 49th Annual Meeting & Exposition of the American Society of Hematology
Novel Steroid-Free Chemotherapy Regimen Shows Promise in Patients with Multiple Myeloma: Dec-06-2007 — Asher A. Chanan-Khan, MD, Department of Medicine, RPCI, presents for the first time the efficacy and toxicity profile of the Bortezomib (V), Doxorubicin and Thalidomide (VDT) regimen in previously untreated multiple myeloma (MM) patients...
Acute Myeloid Leukemia Patient Survival May Depend on Blood Vessel Formation: Dec-06-2007 — Eunice S. Wang, MD, RPCI, presents data suggesting that the tumor microenvironment contributes to the survival of patients diagnosed with acute myeloid leukemia at the 49th Annual Meeting & Exposition of the American Society of Hematology.
Unique Method of Determining the Extent of Multiple Myeloma: Dec-06-2007 — Asher A. Chanan-Khan, MD, RPCI, will describe a unique method of determining the extent of multiple myeloma using magnetic resonance imaging of bone marrow at the 49th Annual Meeting & Exposition of the American Society of Hematology.
Immunochemotherapy Shows Clinical Efficacy Without Cardiac Toxicity: Dec-06-2007 — Myron S. Czuczman, MD, RPCI, will present an update of the phase I/II study showing the efficacy of Rituxan and Doxil in patients with relapsing or refractory B-cell lymphoma at the Annual Meeting & Exposition of the American Society of Hematology.
Understanding Stem Cell Transplantation Risks Can Improve Outcomes: Dec-06-2007 — Identifying leukemia patients at high-risk for complications from allogeneic hematopoietic stem cell transplantation can lead to improved outcomes: Theresa E. Hahn, PhD, RPCI, at the 49th Annual Meeting & Exposition of the American Society of Hematology.
Genetics Predicts Toxicity Following Blood and Marrow Transplantation: Dec-06-2007 — Theresa E. Hahn, PhD, RPCI, presents the results of the first study evaluating regimen-related toxicity after autologous and related and unrelated allogeneic BMT at the 49th Annual Meeting & Exposition of the American Society of Hematology.
Roswell Park Faculty Member Featured Speaker at National Scientific Symposium: Dec-06-2007 — Asher A. Chanan-Khan, MD, Department of Medicine, RPCI, will be a featured speaker at a symposium at the 49th Annual Meeting & Exposition of the American Society of Hematology.
Roswell Park to Investigate Multiple Myeloma: Oct-30-2007 — RPCI's Kelvin P. Lee, MD, has been awarded a grant by the National Cancer Institute to characterize the molecular and cellular components of potential therapeutic targets on multiple myeloma (MM) cells.
International Excellence Award Established for RPCI Researcher: Oct-29-2007 — Thomas J. Dougherty, PhD, Chief Emeritus, Photodynamic Therapy (PDT) Center, RPCI, has been recognized for his contributions and inventions in PDT by the Society of Porphyrins and Phthalocyanines (SPP), headquartered in Dijon, France.
Prostate Cancer Network Honors Roswell Park Scientist: Oct-19-2007 — The Prostate Net presented its annual "In the Know" Award for Clinical Research Excellence to T. Ming Chu, PhD, DSc, Chair Emeritus, Diagnostic Immunology Research, Roswell Park Cancer Institute, at a gala luncheon in New York City.
A New Insight into Regulation of the Body's Defense Against Disease: Oct-10-2007 — The intensity of the immune response to cancer is determined by the genes of each patient, according to researchers in the Department of Molecular and Cellular Biology at RPCI.
National Cancer Institute Awards More Than $4 Million in Grants to Roswell Park Faculty: Oct-03-2007 — The National Cancer Institute has awarded grants totaling $4,044,310 to six members of the Roswell Park Cancer Institute faculty.
Roswell Park Hosts Lecture on Ethics of Human Research: Sep-27-2007 — Robert J. Levine, MD, Co-Director of Yale University's Interdisciplinary Bioethics Center and one of the preeminent figures in the field of ethics of human research will present "The Ethics of Research Involving Human Subjects," at RPCI's Facuty Forum.
RPCI Receives International Recognition for Smoke-Free Research: Sep-24-2007 — The Global Smokefree Partnership (GSP) presented its 2007 GSP Award for Research to RPCI at the meeting of the Society for Research on Nicotine and Tobacco, Rio de Janeiro, Brazil.
Roswell Park Cancer Institute Faculty Awarded $2.1 Million in Grants: Sep-12-2007 — Four faculty members at Roswell Park Cancer Institute have been awarded grants totaling $2,136,589.
Roswell Park Technology Fuels Third Biotech Company: Aug-02-2007 — RPCI and AndroBioSys, Inc. today announced a licensing and investment agreement. ABS will focus its efforts on identifying specific targets in prostate tumors which may be developed to improve prostate cancer treatment.
HuMax-CD20 (ofatumumab) for B-cell CLL: Jul-25-2007 — Roswell Park Cancer Institute seeking patients for Clinical Trial with a new Human antiCD20 antibody for Chronic Lymphocytic Leukemia.
Cancer Vaccine Triggers Immune System in Ovarian Cancer Study: Jul-24-2007 — A therapeutic ovarian cancer vaccine developed by researchers at Roswell Park Cancer Institute (RPCI) has shown promise in a phase I clinical trial.
Roswell Park and Empire Genomics Agree on Memorandum of Understanding: Jul-12-2007 — In a strategic exercise that will help commercialize RPCI genetic and diagnostic technology and further solidify ties with WNY on the Buffalo Niagara Medical Campus, RPCI and Empire Genomics, LLC, have signed a Memorandum of Understanding.
Distinguished Cancer Researcher Appointed at Roswell Park: Jun-13-2007 — Andrei V. Gudkov, PhD, DSci, a pre-eminent cancer researcher has been appointed as Senior Vice President for Basic Research; Chair of the Department of Cell Stress Biology, and member of the senior team for NCI Cancer Center Support Grant at RPCI.
Roswell Park License to BlueGnome, Ltd, Supports Institute Research and Patient Care: Jun-11-2007 — RPCI reports that quarterly royalty payments for its RPCI-BAC-11 library have doubled for the fourth consecutive quarter under a licensing agreement with BlueGnome, Ltd, Cambridge, UK.
Roswell Park Honored with American Cancer Society Grants: May-29-2007 — RPCI has awarded $20,000 in Institutional Research Grants to Andrei Bakin, PhD, Department of Cancer Genetics; Wendy Huss, PhD, Department of Urologic Oncology; and Nithya Ramnath, MD, Department of Medicine solely to support novel projects for junior RPCI faculty.
Roswell Park Research Awarded $300,000 to Study Breast Cancer Risk: May-16-2007 — Susan G. Komen for the Cure has awarded a three-year $300,000 grant to Kirsten Moysich, PhD, Department of Cancer Prevention, Epidemiology and Biostatistics at RPCI to examine the role of a unique type of immune function in the development of breast cancer.
Target for Vitamin D Therapy Identified: Mar-16-2007 — RPCI researchers have identified a mechanism to explain why blood vessel lining cells isolated from tumors are more sensitive to the antiproliferative effects of vitamin D than endothelial cells isolated from tissues (Journal of Biological Chemistry).
Roswell Park Boosts Life Sciences Economy in Upstate New York: Mar-15-2007 — What a banner year it has been so far for Roswell Park Cancer Institute (RPCI). Since the beginning of 2007, the Institute has announced that a highly accomplished cancer researcher and his biomedical company are relocating to Buffalo, and that RPCI laboratory discoveries have led to the creation of a new life sciences spin-off company in Buffalo.
Roswell Park Establishes Life Sciences Company in Buffalo: Jan-18-2007 — RPCI and Boston-based Venzyme Accelerator announced today the formation of PersonaDX, Inc. a new life sciences company, that will be based in Buffalo.